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Abstract 
Background: While the LRRK2 p.G2019S mutation has been demonstrated to be a strong risk 
factor for Parkinson’s Disease (PD), factors that contribute to penetrance among carriers, other 
than aging, have not been well identified.   
Objectives: To evaluate whether a cumulative genetic risk identified in the recent genome-wide 
study is associated with penetrance of PD among p.G2019S mutation carriers. 
Methods: We included p.G2019S heterozygote carriers with European ancestry in three genetic 
cohorts in which the mutation carriers with and without PD were selectively recruited. We also 
included the carriers from two datasets: one from a case-control setting without selection of 
mutation carriers, and the other from a population sampling. The associations between PRS 
constructed from 89 variants reported in Nalls et al. and PD were tested and meta-analyzed. We 
also explored the interaction of age and PRS. 
Results: After excluding 8 homozygotes, 833 p.G2019S heterozygote carriers (439 PD and 394 
unaffected) were analyzed. PRS was associated with a higher penetrance of PD (OR 1.34, 95% 
C.I. [1.09, 1.64] per +1 SD, P = 0.005). In addition, associations with PRS and penetrance were 
stronger in the younger participants (main effect: OR 1.28 [1.04, 1.58] per +1 SD, P = 0.022; 
interaction effect: OR 0.78 [0.64, 0.94] per +1 SD and +10 years of age, P = 0.008).  
Conclusions: Our results suggest that there is a genetic contribution for penetrance of PD among 
p.G2019S carriers. These results have important etiologic consequences and potential impact on 




Parkinson’s disease (PD) is a complex genetic disorder, where rare and highly damaging variants 
as well as common risk variants play a role in its etiology.1  The LRRK2 p.G2019S (rs34637584) 
mutation is one of the major known contributors to PD.2,3 The p.G2019S mutation has an estimated 
prevalence of approximately 1% in the PD population of European ancestry, with much higher 
frequencies being reported for North African Berber Arab populations and European 
subpopulations with high Ashkenazi Jewish ancestry.4–7 The p.G2019S mutation is not fully 
penetrant, with risk of PD for carriers increasing with age. At age 80 years, 25% to 42.5% of 
carriers will have PD.7,8 Critical question that remain centers on what the determinants of 
made available for use under a CC0 license. 
certified by peer review) is the author/funder. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also 
The copyright holder for this preprint (which was notthis version posted August 16, 2019. ; https://doi.org/10.1101/738260doi: bioRxiv preprint 
p.G2019S penetrance are. Previously, it has been reported that a variant in DNM3, encoding the 
vesicular transport protein dynamin 3, is a potential LRRK2 p.G2019S age-at-onset modifier, 
lowering the age at onset by approximately 8 years.9 However, other reports have not replicated 
this finding and instead nominated variants in SNCA as modifiers of LRRK2 mutation penetrance.10 
The underlying pathogenic mechanism of LRRK2-linked PD is currently unknown, but a great deal 
of focus has been placed on the ability of the p.G2019S mutation to increase LRRK2 kinase 
activity, especially since loss-of-function mutations do not seem to be contributing to disease.11,12 
In the last several years, genome-wide association studies (GWAS) have identified an ever-
increasing number of risk loci for PD. Individually, each of these loci confers modest effects on 
risk for disease. Polygenic risk score (PRS) represents known cumulative genetic risk across these 
loci in each assayed individual. PRS reveals that, collectively, these risk variants confer 
considerable risk for disease, with those in the top decile of genetic risk being sixfold more likely 
to have PD than those in the lowest decile of genetic risk in the European population.1 PRS is also 
highly correlated with age at onset of PD,13,14 and is associated with penetrance of damaging GBA 
variants.15 Here, we investigate the influence of the latest PD PRS on age at onset and penetrance 
of PD in p.G2019S carriers using several large cohorts. 
 
Methods 
Whole genome sequencing  
Genetics and clinical data used in the preparation of this article were obtained from the Parkinson’s 
Progression Markers Initiative (PPMI) database (www.ppmi-info.org/data). (For up-to-date 
information on the PPMI study, visit www.ppmi-info.org.) In this study, we included three genetic 
cohorts: Parkinson's Progression Markers Initiative Genetic Cohort (PPMI_GC), Parkinson's 
Progression Markers Initiative Genetic Registry (PPMI_GR), and the LRRK2 Consortium Cohort 
(LCC), hereafter collectively named the Genetic Cohort Dataset. These cohorts selectively 
included people with specific high-risk genetic variants, such as carrying p.G2019S, for both cases 
and unaffected individuals. Whole genome sequencing (WGS) data was generated at the 
Laboratory of Neurogenetics (LNG) at the National Institutes of Health, and detailed methods are 
available from the study website. After downloading, subsequent genotypes were filtered to 
exclude minor allele frequency of less than 0.01, missing rate more than 5%, and the test for 
Hardy–Weinberg equilibrium threshold of 1.0E-4 in controls. Following quality control, 185 
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carriers of p.G2019S (PD/Non-PD = 88/97) in PPMI_GC, 75 (38/37) in PPMI_GR, and 175 
(107/68) in LCC were included in the analysis. Among them, 7 individuals (3 in PPMI_GC, 3 in 
PPMI_GR, and 1 in LCC, all cases) were homozygotes. 
 
Genotype data from the International Parkinson Disease Genomics Consortium 
Aggregated genotype data was obtained from the International Parkinson Disease Genomics 
Consortium (IPDGC), as previously described.1 In brief, genotypes were processed using standard 
pipelines and imputed using the HRC imputation panel r1.1 201616 via the Michigan imputation 
server under the default setting with phasing using the EAGLE option.17 Genotypes were filtered 
for imputation quality R2 > 0.8. Following quality control criteria similar to that applied to the 
Genetic Cohort Dataset, a total of 227 carriers were included in the analysis, of which 208 were 
PD cases and 19 were controls. Among them, one PD patient was homozygous. For composing 
PRS, we used a threshold of R2 > 0.3 to obtain dosages of more risk-associated alleles because 
only 64 variants were passed with the cutoff of 0.8 in R2.  
 
UK Biobank data 
The United Kingdom (UK) Biobank (UKBB) is a large, long-term biobank study in the UK that 
includes genetic data and a wide range of phenotypes of approximately 500,000 individuals.18 PD 
case-control status was based on multiple field codes, including 41202, 41204, 40002, and 20002. 
LRRK2 p.G2019S was directly genotyped in the UK Biobank cohort (rs34637584, n = 314), and 
the concordance rate in the whole-exome sequencing data19 was 100%. After applying the same 
quality control steps as above, 179 carriers were identified, of which 6 were reported to be PD 
cases; all were heterozygotes. 
 
Polygenic risk score calculation 
PRS was calculated incorporating the risk loci previously associated with PD.1 In the calculation 
of PRS, risk allele dosages were summed with weights as their published beta estimates, giving 
greater weight to alleles with higher estimates. Then, PRS were standardized to each cohort level. 
For the UKBB and IPDGC imputed genotype data, not all 89 variants were available due to lower 
imputation scores (R2 > 0.8 for UKBB and R2 > 0.3 for IPDGC); therefore, 88 variants in UKBB 
and a median of 89 variants (range: 82–89) in IPDGC were used.  
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Statistical analysis 
Our primary analysis was to test the association between PRS and PD odds using a fixed effect 
meta-analysis model among the mutation carriers. First, a logistic regression model was applied 
for the main effect of PRS for the Genetic Cohort Dataset (PPMI_GC/PPMI_GR/LRRK2), IPDGC 
dataset, and UKBB dataset separately. The data were adjusted for age, sex, cohort, and PCs 
representing population structure. Across all datasets, the linear age upon recruitment was used for 
carriers without PD and the age at diagnosis for carriers with PD, whereas the age at onset was 
used for the IPDGC dataset and the age at recruitment for the UKBB dataset. The age data were 
centered—the original value subtracted by the mean age at each cohort—to accommodate square 
age variable in the later step. To adjust for population structure, PC1–10 were used for the Genetic 
Cohort Dataset and IPDGC dataset, and PC1–5 were used for the UKBB dataset because of its 
size. 
In the secondary analysis, the interaction between age and PRS for PD odds was tested. In this 
analysis, we excluded the UKBB dataset because of the small number of PD cases. We meta-
analyzed the dataset level ORs for the main effect and the interaction effect between age and PRS 
as in the similar model above, but we further adjusted for square age in the Genetic Cohort Dataset 
and IPDGC dataset. Square age was significantly associated with the PD odds in these two 
datasets; as the UKBB dataset cannot accommodate the variable because of too few PD cases, we 
thus could not include square age in the primary analysis.  
Also, the association of PRS on age at diagnosis (Genetic Cohort Dataset) or age at onset (IPDGC 
dataset) for the carriers with PD was analyzed in an exploratory manner. Adjusted covariates 
included age, square age, sex, cohorts, and PC1–10.  
There were 8 homozygotes of p.G2019S mutation in the analysis set, and we excluded them from 
all analyses. Analyses were conducted by using R version 3.5.1(https://cran.r-project.org/), with a 
significance level of 0.05 (two-sided). With the sample size here, we had 90% power for the 
primary analysis and 35% power for the exploratory analysis on age at onset/diagnosis, assuming 
that the associations were the same as in the previous report conducted in a general case-control 
setting in the European population.1  
 
Patients Consent 
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Participants’ information and genetic samples were obtained under appropriate written consent 




Table 1 is a summary of participants with and without the LRRK2 p.G2019S mutation in the 
datasets under study. The IPDGC dataset consists of 14,225 cases and 16,543 controls with known 
LRRK2 p.G2019S status; only 1.4% of the cases had the LRRK2 p.G2019S mutation, and 0.11% 
of the controls carried the mutation. The prevalence of PD in carriers is consistent with results 
from a previous report of 1% of PD patients carrying the mutation.7 Among the 362,884 
participants passing filtering criteria in the UKBB, 0.049% were carriers of the LRRK2 p.G2019S 
mutation. While the overall prevalence of PD in this dataset was 0.33%, 3.36% of carriers had PD, 
indicating an approximately 10 times higher crude risk of PD associated with the mutation. This 
is consistent with the crude relative risk of 13 in UKBB. In total, of 3 datasets there were 8 
homozygotes reported as PD cases. They had a higher PRS and older age at diagnosis compared 
to heterozygous PD cases (Supplemental Table 1), although the differences were not statistically 




Genetic risk score modifies penetrance of LRRK2 p.G2019S 
The unadjusted plots of PRS among cases and unaffected individuals in the Genetic Cohort Dataset 
showed that the mean of the PRS was higher in cases among carriers (Figure 1). The means of 
PRS in cases were also higher than those in controls among noncarriers in the IPDGC and UKBB 
datasets (Supplemental Figure 1). Meta-analysis results of the three datasets showed that a higher 
PRS was significantly associated with a higher odds ratio of PD (OR 1.34, 95% C.I. [1.09, 1.64] 
per + 1SD [per standard deviation of increase from the cohort mean, P = 0.005]; Figure 2A).  
 
Stronger association of genetic risk score for PD penetrance in younger carriers 
In the secondary analysis examining the interaction between PRS and age, the main effect of PRS 
as well as the interaction between PRS and age were significantly associated with the odds of PD, 
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but in the opposite direction (main effect: OR 1.28 [1.04, 1.58] per +1 SD, P = 0.022; interaction 
effect: OR 0.78 [0.64, 0.94] per +1 SD and +10 years of age, P = 0.008; Figure 2B). This suggests 
that in the studied cohorts, the magnitude of association between PRS and PD odds were stronger 
when the age of the participants was younger. We added post-hoc analyses stratified by age (<55 
years old, 55-65 years old and 65< years old) to illustrate the stronger association of PRS in 
younger age in carriers. (Figure 3). The analyses examining the main effect and interaction effect 
among nonmutation carriers in the IPDGC dataset showed that these effects were also significant 
in nonmutation carriers (the main term for +1 SD in PRS: OR 1.6, P = 2.5E-245; the interaction 
term of +1 SD in PRS and +10 years in age: 0.94, P = 1.4E-9). However, the magnitude of the 
interaction effect was smaller than that in LRRK2 p.G2019S carriers, and the magnitudes of 
associations were significantly different between carriers and non-carriers in the test of 
homogeneity (P = 0.044).  
 
 
Genetic risk score and age at onset/diagnosis in LRRK2 p.G2019S cases 
Previously, we have shown that PRS is inversely correlated with age at onset in PD cases.13 In the 
current study, there was insufficient evidence that PRS was significantly associated with age at 
onset/diagnosis of PD in LRRK2 p.G2019S carriers. The directionality was the same as in the 
general population previously studied ( –0.801 [–0.959, –0.643] per +1 SD in PRS), but the 
association did not reach significance level (Supplemental Figure 2). As mentioned in the power 
calculation analyses in Methods, this is an underpowered study, and therefore additional data is 
needed to confirm these results. 
 
Exploratory analysis for the individual Parkinson’s disease-associated variants 
While the power of the study is not sufficient, the motivation for this analysis was to qualitatively 
assess whether any of the risk variants could be strong penetrance modifiers. The Q-Q plot for the 
observed and expected P in -log10 scale showed an upper deviation from the expected line (lambda 
value of 1.34), indicating the contribution of these variants for the PD risk in p.G2019 LRRK2 
heterozygous carriers. However, no single association stood out as a possible penetrance modifier 
after adjusting for multiple tests (Supplemental Figure 3). Furthermore, when the estimates for the 
associations of carriers and noncarriers of individual variants were compared, there were 10 
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variants whose tests of homogeneity were rejected at a significance level of 0.05 (Supplemental 
Figure 4, Supplemental Table 2). Additionally, GBA mutations in LRRK2 p.G2019S carriers 
(Supplemental Table 3) were analyzed, but there was no clear enrichment of GBA mutations in 
cases versus controls or for younger age at onset among cases. 
 
Discussion 
The aggregated genetic risks in the form of PRS that were constructed from the recent case-control 
GWAS of European population was significantly associated with the risk of PD among 
heterozygous LRRK2 p.G2019S mutation carriers in our study. Furthermore, the magnitude of the 
association was larger in the younger population, and this interaction between age and PRS was 
significantly larger than in noncarriers. Conversely, the age at onset or the age at diagnosis among 
carriers with PD was not significantly associated with PRS, likely due to the small study size rather 
than a truly null association. Additionally, although age at onset and age at diagnosis is highly 
correlated, clinical site variation and differences in assessing this could affect the analysis. 
Therefore, more data are required to conclusively determine this point.  
When we investigated specific variants of interest for PD, such as GBA coding variants and PD 
GWAS variants, no significant differences were identified, although relatively small numbers of 
GBA coding variants did not seem to affect LRRK2 penetrance, which is in line with previous 
results.20 The effect size of 10 PD GWAS variants were heterogeneous between p.G2019S carriers 
and noncarriers at an unadjusted significance level of 0.05. We need more data to formally assess 
these different associations for PD between carriers and noncarriers, but genes in these loci are 
good candidates as potential interactors. Interestingly, rs823118 has a larger effect size and is a 
locus that harbors an RAB7L1, which is a LRRK2 interactor.21 Alsp the effect size of rs1293298 
(CTSB locus) is opposite compared to general PD, where the rs1293298 locus was recently shown 
to be a potential genetic modifier of GBA-associated PD.15 
The primary limitation of this study is the size, despite including several large cohorts. LRRK2 
p.G2019S is rare in the general population, and therefore actively recruiting carriers would be a 
good strategy to increase power for studies such as ours. To investigate the penetrance of carriers, 
recruitment only focusing on carriers are very effective, as shown in Table 1. More initiatives and 
future collaboration with clinical trials only targeting LRRK2 p.G2019S mutations are warranted. 
Currently, there are at least three clinical trials targeting LRRK2-linked PD: two use kinase 
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inhibition, and the third focuses on reducing the protein load. As these trials move forward, 
important considerations are whether the disease mechanisms that cause LRRK2-linked PD are 
generalizable to typical PD, and whether it is possible to identify which LRRK2 mutation carriers 
will or will not express disease. Previously, we have shown that active randomization on genetic 
components of PD is important for successful clinical trials because unbalanced genetic risk may 
lead to the heterogeneity of intervention arms and lower the power of that trial.22 Our results 
suggest that actively balancing PRS is similarly important for a disease modifying/preventing trial 
targeting p.G2019S carriers. 
Taken together, we show that penetrance and likely age at onset of LRRK2 is modified by PD PRS, 
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Figures 
Figure 1: PRS of cases and controls in genetic cohorts 
Legend: The means of PRS in cases were higher than unaffected among LRRK2 p.G2019S 
mutation carriers. LCC, LRRK2 Consortium Cohort; PPMI_GC, Parkinson's Progression 




Figure 2: Meta-analysis for PRS, and its interaction with age on penetrance 
Legend:  
A. Primary analysis of testing the association between PRS and PD showed that PRS was 
significantly associated with the PD odds.  
B. Secondary analysis model with PRS and the interaction between PRS and age showed 
that the main effect of PRS as well as the interaction between PRS and age were 
significantly associated with the odds of PD, but in the opposite direction. Compared to 
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the interaction effect among non-carriers in IPDGC, the magnitude of the interaction 
among the mutation carriers was large. 
OR, Odds ratio; I_sq, I square (%); Q-test, P-value for the test of Heterogeneity; IPDGC, 
International Parkinson Disease Genomics Consortium. Odds ratio were adjusted for study, age, 
square age, sex and PC1-10 
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Figure 3: Age stratified associations of PRS on penetrance in Genetics Cohorts Dataset 
Legend: Age stratified analysis showed that PRS was significantly associated with the younger 
age. OR, Odds ratio; I_sq, I square (%); Q-test, P-value for the test of Heterogeneity. Odds ratio 
were adjusted for study, age, square age, sex and PC1-10 
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Tables 




(N of Homozygotes) 
 p.G2019S noncarriers  
 
Datasets and Cohorts Unaffected PD   Control PD  TOTAL 
Genetic Cohort Dataset (WGS)       
    PPMI Genetic Cohort (PPMI_GC) 97 (0) 88 (3)  - -  185 
    PPMI Genetic Registry (PPMI_GR) 37 (0) 38 (3)  - - 75 
    LRRK2 Consortium Cohort (LCC) 68 (0) 107 (1)  - - 175 
General Case/Control cohort (genotyped)       
    IPDGC (11 cohorts) 19 (0) 208 (1)  16,524 14,217 30,968 
General population cohort (genotyped)       
    UK Biobank 173 (0) 6 (0)  361,531 1,174 362,884 
TOTAL 394 (0) 447 (8)  378,055 15,391 394,287 
IPDGC, International Parkinson Disease Genomics Consortium 
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